spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

3D Cell Culture 2018

21-22 February 2018
Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.

3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different fields, such as 3D bioprinting and microfluidics.

The 2nd annual conference will explore these overlapping areas and will combine pioneering breakthroughs with scientific research to strengthen your commercial success. Join us for exclusive insight into key topics such as disease models, organoids, organ-on-a-chip technologies, iPSC advances plus much more!

FEATURED SPEAKERS:

·        Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience

·        Mr Stefan Przyborski, Scientific Founder, ReInnervate Limited

·        Mr Ricardo Baptista, Lead Scientist Process Development, Cell and Gene Therapy Catapult

·        Dr Nicholas Leslie, Tumour Biologist, Heriot-Watt University

·        Dr Suwan Jaysinghe, Professor of Bioengineering, University College London

·        Dr Max Salick, Postdoctoral Researcher, Novartis Institutes for Biomedical Research

·        Dr Patrick Kugelmeier, Director of Science, Kugelmeiers

·        Dr Vitor Santo, Senior Scientist, Immunocore

·        Mr Christopher Schofield, Investigator, GSK

·        Mr David Pan, Programme Manager (Regenerative Medicine), UK Regenerative Medicine Platform

·        Dr Reyk Horland,Head of Business Development, TissUse GmbH


REASONS TO ATTEND IN 2018

·        Uncover the biology of human neurodevelopment diseases in 3D by merging cutting edge technologies in CRISPR editing and single cell sequencing

·        Take a 3D biology approach to overcome challenges for well based screening with exclusive insight into electrospun micro-scaffold based biology

·        Develop strategies for optimising placement of cells in printing by identifying key developments in the overlap of 3D bioprinting and 3D cell culturing

·        Discover new approaches to predictive substance testing through innovative case study insight into multi-organ-chip technology

·        Benefit from an agenda tailored towards driving clinical development through ground breaking case studies on the Zika virus and tuberous sclerosis


2017 ATTENDEE TESTIMONIALS

“Very good presentations and a few outstanding ones... I made some useful contacts” ASTERAND BIOSCIENCE

“The conference was wonderfully organised” NOVARTIS

“Good start, love to see the event occur again” THERMO FISHER SCIENTIFIC

For further details visit www.3D-cellculture.com/samedan or contact the team on +44 (0)20 7827 6000

 

 
Print this page
Send to a friend
   
spacer
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>


News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement